28 September 2016
The working group was created as part of an objective to reinforce collaboration between the international agencies to address a variety of issues including biosimilars, orphan drugs, and patient safety. To collaborate on a regulatory approach to the development of treatments for rare diseases, the agencies plan on exchanging information on the design of clinical trials in small populations and the use of statistical analysis methods; the selection and validation of trial endpoints; preclinical evidence to support development programs; the design of post-marketing studies; and risk management strategies for long-term safety issues with medicines for rare diseases.
The cluster plans on having monthly teleconference meetings jointly chaired by FDA and EMA.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024